←
Michael Boffa3,999 posts
Michael Boffa avatar

Michael Boffa

@MBBoffa

Gone

◷ Joined November 2012▧ 363 Photos and videos
National Lipid Association avatar
⟳ Michael Boffa retweeted
National Lipid Association@nationallipid·Nov 13

Lipoprotein(a), or Lp(a), remains an important and independent risk factor for ASCVD, and clinicians and patients should continue to measure it. In the latest Lipid Insights episode, host Peter H. Jones, MD, MNLA is joined by leading Lp(a) experts Michael B. Boffa, PhD, and Marlys L. Koschinsky, PhD, FNLA, to react to the Lp(a)HORIZON trial results and discuss what’s next for Lp(a) in cardiovascular prevention. Watch on YouTube or listen on your favorite podcast platform. ▶️ youtu.be/iaqsKJHuLIM #Lipidology #Lipoproteina #Lpa #CardiovascularPrevention

1:26
Pablo Corral MD avatar
⟳ Michael Boffa retweeted
Pablo Corral MD@drpablocorral·Nov 13

👉 MUST READ; A landmark EAS Statement in the post-Lp(a)HORIZON era in @ATHjournal ☝️The European Atherosclerosis Society @society_eas delivers a timely, evidence-based message following the neutral results of Lp(a)HORIZON. 1️⃣ 78% Lp(a) reduction ≠ cardiovascular benefit. We must distinguish a causal risk factor from a validated therapeutic target. 2️⃣ Lp(a) remains a major cardiovascular risk factor. Measure it at least once in every adult. Family screening remains essential. 3️⃣ LDL-C lowering is our strongest actionable strategy. Intensive control of LDL-C and other risk factors can mitigate Lp(a)-associated risk. 4️⃣ Timing may be everything. Can a few years of treatment reverse decades of cumulative atherogenic exposure? 5️⃣ The science is far from over. Ongoing RCTs with different Lp(a)-lowering agents are essential. ☝️My key takeaway: A negative trial should change our assumptions, not replace scientific evidence with speculation. ☝️ Measure Lp(a). Lower LDL-C. Control global risk. Keep testing hypotheses with RCTs. 🔗 atherosclerosis-journal.com/… @BNordestgaard @ProfKausikRay @MeralKayikcoglu @KronenbergLab @j_rvl @SamiaMoraMD

Post attachment
Thomas Dayspring avatar
⟳ Michael Boffa retweeted
Thomas Dayspring@Drlipid·Nov 11

For more on Lp(a) - this podcast featuring world-class Lp(a) scientists @MarlysLPA and @MBBoffa is easily worth 30 minutes of one's time @ASPCardio @society_eas @escardio @atherosociety @TheEndoSociety @FamilyHeartFdn @fhpatienteurope

The primary results from the Lp(a)HORIZON trial were presented at #AHA26 in Chicago on November 7. Although pelacarsen lowered lipoprotein(a) [Lp(a)] levels, the trial did not reduce the risk of major adverse cardiovascular events (MACE). In the latest Lipid Insights episode, host Peter H. Jones, MD, MNLA sits down with two leading Lp(a) experts, Michael B. Boffa, PhD, and Marlys L. Koschinsky, PhD, FNLA, to react to the results and discuss what’s next for Lp(a) in cardiovascular prevention. Watch on YouTube or listen on your favorite podcast platform. ▶️ youtu.be/iaqsKJHuLIM #Lipidology #Lipoproteina #Lpa #CardiovascularPrevention

1:05
Precision Health Reports 📑❤️ avatar
⟳ Michael Boffa retweeted
Precision Health Reports 📑❤️@PreciseHlthRpt·10 Sep 2025

One key fact that everyone should know about Lp(a): Comprehensive cardiometabolic screening and management using just lipids and basic biometrics is incomplete without also considering a one-time Lp(a) value for the individual. Lp(a) + lipoproteins + IR + glycemic status + noninvasive imaging results + inflammation + biometrics + clinical history

Dr. Jonathan N. Stea avatar
⟳ Michael Boffa retweeted
Dr. Jonathan N. Stea@jonathanstea·3 Nov 2024

Social media is that special place where you can find someone trying to explain The Handmaid’s Tale to the author of The Handmaid’s Tale.

Post attachment
Michael Boffa avatar
Michael Boffa@MBBoffa·4 Oct 2024

Our latest review article on Lp(a), which actually made the cover of Biochemical Journal! As before this journal, we go into some depth on the more basic molecular details of Lp(a). Enjoy! @MarlysLPA portlandpress.com/biochemj/a…